North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group

 
back
8 Malignant disease and immunosuppression

For the most up to date list of agents funded by the Cancer Drugs Fund, please see Cancer Drug Fund List

The list should be read in conjunction with Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund).

08-03-04-03 Somatostatin analogues

Lanreotide acetate
Formulary
  • Non NHS England indications i.e. palliative care

Somatuline® LA (lanreotide acetate) 30mg powder and solvent for suspension for injection vials 

Somatuline® Autogel (lanreotide acetate) 120mg per 1ml solution for injection pre-filled syringes with safety system 

Somatuline® Autogel (lanreotide acetate) 180mg per 1ml solution for injection pre-filled syringes with safety system 

Somatuline® Autogel (lanreotide acetate) 240mg per 1ml solution for injection pre-filled syringes with safety system

 


Amber View adult BNF  View SPC online  View childrens BNF  HCD
Lanreotide acetate
Formulary

Restriction: In accordance with NHS England prescribing policy

  • Acromegaly
  • Cancer indication
  • Congenital hyperinsulism

Somatuline® LA (lanreotide acetate) 30mg powder and solvent for suspension for injection vials 

Somatuline® Autogel (lanreotide acetate) 120mg per 1ml solution for injection pre-filled syringes with safety system 

Somatuline® Autogel (lanreotide acetate) 180mg per 1ml solution for injection pre-filled syringes with safety system 

Somatuline® Autogel (lanreotide acetate) 240mg per 1ml solution for injection pre-filled syringes with safety system

 


Red View adult BNF  View SPC online  View childrens BNF  HCD
Lutetium (177Lu) oxodotreotide
Formulary

Restriction: In line with NICE Guidance only

Lutathera 370 MBq/mL solution for infusion

Link  NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
 

Cytotoxic Drug  Red  HCD  CDF
Octreotide acetate
Formulary
  • Non NHS England indications i.e. palliative care

Octreotide acetate 50microgram per 1ml solution for injection ampoules
Octreotide acetate 50microgram per 1ml solution for injection pre-filled syringes

Octreotide acetate 100microgram per 1ml solution for injection ampoules
Octreotide acetate 100microgram per 1ml solution for injection pre-filled syringes

Octreotide acetate 500microgram per 1ml solution for injection ampoules
Octreotide acetate 500microgram per 1ml solution for injection pre-filled syringes

Octreotide acetate 1mg per 5ml solution for injection vials

Sandostatin® LAR 10mg powder and solvent for injection vials
Sandostatin® LAR 20mg powder and solvent for injection vials
Sandostatin® LAR 30mg powder and solvent for injection vials


Amber View adult BNF  View SPC online  View childrens BNF  HCD
Octreotide acetate
Formulary

Restriction: In accordance with NHS England prescribing policy

  • Acromegaly
  • Cancer indication
  • Congenital hyperinsulism

Octreotide acetate 50microgram per 1ml solution for injection ampoules

Octreotide acetate 50microgram per 1ml solution for injection ampoules
Octreotide acetate 50microgram per 1ml solution for injection pre-filled syringes

Octreotide acetate 100microgram per 1ml solution for injection ampoules
Octreotide acetate 100microgram per 1ml solution for injection pre-filled syringes

Octreotide acetate 500microgram per 1ml solution for injection ampoules
Octreotide acetate 500microgram per 1ml solution for injection pre-filled syringes

Octreotide acetate 1mg per 5ml solution for injection vials

Sandostatin® LAR 10mg powder and solvent for injection vials
Sandostatin® LAR 20mg powder and solvent for injection vials
Sandostatin® LAR 30mg powder and solvent for injection vials


Red View adult BNF  View SPC online  View childrens BNF  HCD